Investigating new antiretroviral combinations [1]

Journal of Infectious Diseases

Volumn 193, Issue 12, 2006, Pages 1742-

  Carr, Andrew ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; LAMIVUDINE; TENOFOVIR;

ANTIBIOTIC RESISTANCE; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE;

ADENINE; ANTI-HIV AGENTS; DIDEOXYNUCLEOSIDES; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; LAMIVUDINE; PHOSPHONIC ACIDS; PILOT PROJECTS; RANDOMIZED CONTROLLED TRIALS;

EID: 33744814605     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/504296     Document Type: Letter

References (3)

1. Gallant JE, Rodriguez AE, Weinberg WG, et al. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis 2005; 192: 1921-30.
2. Kuritzkes DR. Less than the sum of its parts: failure of a tenofovir-abacavir-lamivudine triple-nucleoside regimen. J Infect Dis 2005; 192: 1867-8.
3. Hirsch MS, Brun-Vézinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2003; 37:113-28.